Eliem Therapeutics Inc (ELYM)
7.59
-0.07
(-0.91%)
USD |
NASDAQ |
May 31, 16:00
7.68
+0.09
(+1.19%)
After-Hours: 20:00
Eliem Therapeutics Cash from Operations (TTM): -7.241M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -7.241M |
December 31, 2023 | -20.60M |
September 30, 2023 | -28.10M |
June 30, 2023 | -35.77M |
March 31, 2023 | -41.77M |
December 31, 2022 | -37.37M |
September 30, 2022 | -36.80M |
Date | Value |
---|---|
June 30, 2022 | -45.60M |
March 31, 2022 | -40.11M |
December 31, 2021 | -36.07M |
September 30, 2021 | -33.81M |
June 30, 2021 | -23.23M |
March 31, 2021 | -18.51M |
December 31, 2020 | -14.10M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-45.60M
Minimum
Jun 2022
-7.241M
Maximum
Mar 2024
-29.93M
Average
-34.79M
Median
Cash from Operations (TTM) Benchmarks
Alpine Immune Sciences Inc (DELISTED) | -80.55M |
Candel Therapeutics Inc | -31.86M |
Cyclacel Pharmaceuticals Inc | -9.734M |
Lipocine Inc | -5.530M |
GlycoMimetics Inc | -33.78M |